PERCEPTIVE ADVISORS LLC
13F Reported Value
ⓘ$5.1B
incl. option notional
Equity Holdings
ⓘ$5.1B
Option Notional
ⓘ$55.0M
$50.8M puts / $4.2M calls
Holdings
94
Latest Filing
2026-03-31
Filing Quarter
Q1 2026
Portfolio Overview
PERCEPTIVE ADVISORS LLC disclosed 94 positions worth $5.1B in its Form 13F-HR for Q1 2026 — $5.1B in common stock plus $55.0M of put/call option positions (reported at underlying notional value, not premium at risk), led by $PRAX (Praxis Precision Medicines, Inc.) at 13.0% of the equity portfolio, followed by $CELC and $ASND. During the quarter the fund opened 18 new positions and exited 42 — including a new stake in $MRNA. The portfolio is most concentrated in Healthcare (99.0% of disclosed assets). All figures are sourced directly from PERCEPTIVE ADVISORS LLC’s Form 13F-HR filing with the SEC under CIK 1224962.
AI Fund Analysis
ConcentratingSector Allocation
AUM History
Top Equity Holdings by Value
Option Positions
13F rules report options at the value of the underlying shares (notional) — not the premium paid or capital at risk. Shown separately from the equity sleeve above.
Quarterly Activity — Q1 2026
Click any card to unlockTop Holdings
- $656.0M2,035,986 sh
- —
Quality
$356.9M3,127,200 sh - 41.5#1,891
Quality
$350.3M1,531,421 sh - —
Quality
$229.5M8,285,461 sh - —
Quality
$208.9M5,258,903 sh - 30.3
Quality
$206.4M2,373,795 sh - —
Quality
$190.8M3,783,225 sh - —
Quality
$161.9M1,580,505 sh - —
Quality
$139.4M4,423,974 sh - 24.8
Quality
$129.7M1,230,879 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
 Praxis Precision Medicines, Inc.$PRAX | — | $656.0M | 2,035,986 |
 Celcuity Inc.$CELC | — | $356.9M | 3,127,200 |
 Ascendis Pharma A/S$ASND | 41.5#1,891 | $350.3M | 1,531,421 |
 Roivant Sciences Ltd.$ROIV | — | $229.5M | 8,285,461 |
 Centessa Pharmaceuticals plc$CNTA | — | $208.9M | 5,258,903 |
 RHYTHM PHARMACEUTICALS, INC.$RYTM | 30.3 | $206.4M | 2,373,795 |
 Spyre Therapeutics, Inc.$SYRE | — | $190.8M | 3,783,225 |
 Nuvalent, Inc.$NUVL | — | $161.9M | 1,580,505 |
 Edgewise Therapeutics, Inc.$EWTX | — | $139.4M | 4,423,974 |
 Protagonist Therapeutics, Inc$PTGX | 24.8 | $129.7M | 1,230,879 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of PERCEPTIVE ADVISORS LLC's 94 positions.
Showing top 10 of 94 holdings.
Sector Allocation
Healthcare
$5.0B
Technology
$48.9M
Full Holdings — PERCEPTIVE ADVISORS LLC (Q1 2026)
All 94 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $PRAX | Praxis Precision Medicines, Inc. | $656.0M | 13.0% | +2% | — |
| 2 | $CELC | Celcuity Inc. | $356.9M | 7.1% | -1% | — |
| 3 | $ASND | Ascendis Pharma A/S | $350.3M | 6.9% | +42% | 41.5 |
| 4 | $ROIV | Roivant Sciences Ltd. | $229.5M | 4.5% | +4% | — |
| 5 | $CNTA | Centessa Pharmaceuticals plc | $208.9M | 4.1% | +80% | — |
| 6 | $RYTM | RHYTHM PHARMACEUTICALS, INC. | $206.4M | 4.1% | -7% | 30.3 |
| 7 | $SYRE | Spyre Therapeutics, Inc. | $190.8M | 3.8% | +23% | — |
| 8 | $NUVL | Nuvalent, Inc. | $161.9M | 3.2% | -5% | — |
| 9 | $EWTX | Edgewise Therapeutics, Inc. | $139.4M | 2.8% | -1% | — |
| 10 | $PTGX | Protagonist Therapeutics, Inc | $129.7M | 2.6% | -9% | 24.8 |
| 11 |  $APGE | Apogee Therapeutics, Inc. | $129.7M | 2.6% | -34% | — |
| 12 |  $TVTX | Travere Therapeutics, Inc. | $123.1M | 2.4% | -3% | 39.2 |
| 13 |  $AMLX | Amylyx Pharmaceuticals, Inc. | $115.2M | 2.3% | +0% | — |
| 14 |  $IMTX | Immatics N.V. | $102.2M | 2.0% | +0% | — |
| 15 |  $RLAY | Relay Therapeutics, Inc. | $97.0M | 1.9% | +412% | 12.7 |
| 16 |  $INBX | Inhibrx Biosciences, Inc. | $97.0M | 1.9% | -1% | 3.1 |
| 17 |  $MGTX | MeiraGTx Holdings plc | $89.3M | 1.8% | +0% | — |
| 18 |  $ZYME | Zymeworks Inc. | $87.9M | 1.7% | +8% | 27.2 |
| 19 |  $SLDB | Solid Biosciences Inc. | $85.7M | 1.7% | +1% | — |
| 20 |  $DYN | Dyne Therapeutics, Inc. | $84.6M | 1.7% | +34% | — |
| 21 |  $BCRX | BIOCRYST PHARMACEUTICALS INC | $70.8M | 1.4% | +135% | 37.2 |
| 22 |  $ORKA | Oruka Therapeutics, Inc. | $68.4M | 1.4% | -5% | — |
| 23 |  $AORT | ARTIVION, INC. | $60.0M | 1.2% | -5% | 48.8 |
| 24 |  $NRIX | Nurix Therapeutics, Inc. | $57.5M | 1.1% | +4% | 13.2 |
| 25 |  $MRNAPUT | Moderna, Inc. | $50.8M | — | NEW | 15.9 |
| 26 |  $NAUT | Nautilus Biotechnology, Inc. | $48.9M | 1.0% | +0% | — |
| 27 |  $CTMX | CytomX Therapeutics, Inc. | $47.5M | 0.9% | +4% | 19.1 |
| 28 |  $ANRO | Alto Neuroscience, Inc. | $45.2M | 0.9% | +13% | — |
| 29 |  $ENGN | enGene Therapeutics Inc. | $39.7M | 0.8% | -1% | — |
| 30 |  $IMVT | Immunovant, Inc. | $39.7M | 0.8% | -20% | — |
| 31 |  $ISRG | INTUITIVE SURGICAL INC | $39.4M | 0.8% | -3% | 81.4 |
| 32 |  $IONS | IONIS PHARMACEUTICALS INC | $37.8M | 0.8% | NEW | 37.1 |
| 33 |  $DAWN | Day One Biopharmaceuticals, Inc. | $37.6M | 0.7% | NEW | 42.6 |
| 34 |  $ABVX | Abivax S.A. | $36.6M | 0.7% | -28% | — |
| 35 |  $CRVS | Corvus Pharmaceuticals, Inc. | $33.5M | 0.7% | +231% | — |
| 36 |  $RGEN | REPLIGEN CORP | $33.1M | 0.7% | -11% | 54.1 |
| 37 |  $JAZZ | Jazz Pharmaceuticals plc | $32.1M | 0.6% | +0% | — |
| 38 |  $DMRA | Damora Therapeutics, Inc. | $31.7M | 0.6% | NEW | — |
| 39 |  $XFOR | X4 Pharmaceuticals, Inc | $27.8M | 0.6% | +7% | 29.3 |
| 40 |  $GH | Guardant Health, Inc. | $27.7M | 0.6% | +88% | 36.1 |
| 41 |  $DRUG | BRIGHT MINDS BIOSCIENCES INC. | $27.5M | 0.5% | -16% | — |
| 42 |  $IVVD | Invivyd, Inc. | $27.1M | 0.5% | -4% | 25.7 |
| 43 |  $SION | Sionna Therapeutics, Inc. | $26.4M | 0.5% | -44% | — |
| 44 |  $AXSM | Axsome Therapeutics, Inc. | $25.3M | 0.5% | +1% | 36.6 |
| 45 |  $RVMD | Revolution Medicines, Inc. | $25.1M | 0.5% | NEW | — |
| 46 |  $SABS | SAB Biotherapeutics, Inc. | $24.6M | 0.5% | +701% | — |
| 47 |  $BLTE | BELITE BIO, INC | $24.2M | 0.5% | -63% | — |
| 48 |  $TENX | TENAX THERAPEUTICS, INC. | $23.2M | 0.5% | +230% | — |
| 49 |  $AXGN | Axogen, Inc. | $23.1M | 0.5% | -11% | 38 |
| 50 |  $VRDN | Viridian Therapeutics, Inc.\DE | $22.9M | 0.5% | -62% | 30.5 |
| 51 |  $OBIO | Orchestra BioMed Holdings, Inc. | $21.4M | 0.4% | -2% | 8.7 |
| 52 |  $RAPP | Rapport Therapeutics, Inc. | $21.1M | 0.4% | +0% | — |
| 53 |  $DBVT | DBV Technologies S.A. | $20.1M | 0.4% | NEW | 6.1 |
| 54 |  $LONA | LeonaBio, Inc. | $19.1M | 0.4% | +0% | — |
| 55 |  $AVR | Anteris Technologies Global Corp. | $19.0M | 0.4% | +104% | — |
| 56 |  $STRO | SUTRO BIOPHARMA, INC. | $17.8M | 0.3% | NEW | 30.1 |
| 57 |  $TNGX | Tango Therapeutics, Inc. | $16.9M | 0.3% | +58% | 26.9 |
| 58 |  $CTNM | Contineum Therapeutics, Inc. | $16.4M | 0.3% | -14% | — |
| 59 | $CELC | Celcuity Inc. | $15.9M | 0.3% | +0% | — |
| 60 |  $PALI | PALISADE BIO, INC. | $15.6M | 0.3% | -26% | — |
| 61 |  $OCS | Oculis Holding AG | $13.1M | 0.3% | +0% | — |
| 62 |  $IRTC | iRhythm Holdings, Inc. | $12.4M | 0.3% | -3% | 41.1 |
| 63 |  $EVMN | Evommune, Inc. | $10.3M | 0.2% | NEW | — |
| 64 |  $PHAT | Phathom Pharmaceuticals, Inc. | $10.3M | 0.2% | NEW | 32.5 |
| 65 |  $NMRA | Neumora Therapeutics, Inc. | $10.0M | 0.2% | NEW | — |
| 66 |  $OMDA | Omada Health, Inc. | $9.9M | 0.2% | -67% | 45.5 |
| 67 |  $NBIX | NEUROCRINE BIOSCIENCES INC | $8.6M | 0.2% | -80% | 75.4 |
| 68 |  $BBNX | Beta Bionics, Inc. | $8.4M | 0.2% | +40% | 22.8 |
| 69 |  $IRD | Opus Genetics, Inc. | $8.4M | 0.2% | -58% | — |
| 70 |  $BLLN | BillionToOne, Inc. | $7.2M | 0.1% | +26% | — |
| 71 |  $TWST | Twist Bioscience Corp | $7.1M | 0.1% | NEW | 33.3 |
| 72 |  $SRZN | Surrozen, Inc./DE | $6.7M | 0.1% | NEW | — |
| 73 |  $AGMB | Agomab Therapeutics NV | $6.3M | 0.1% | NEW | — |
| 74 |  $EOLS | Evolus, Inc. | $5.3M | 0.1% | NEW | 30 |
| 75 |  $COGT | Cogent Biosciences, Inc. | $4.7M | 0.1% | +0% | — |
| 76 |  $ADGM | Adagio Medical Holdings, Inc. | $4.3M | 0.1% | -62% | — |
| 77 |  $OCULCALL | OCULAR THERAPEUTIX, INC | $4.2M | — | NEW | 12.8 |
| 78 |  $ADMA | ADMA BIOLOGICS, INC. | $4.2M | 0.1% | -47% | 76 |
| 79 |  $IKT | Inhibikase Therapeutics, Inc. | $3.9M | 0.1% | -57% | — |
| 80 |  $CBIO | CRESCENT BIOPHARMA, INC. | $3.8M | 0.1% | -54% | 28 |
| 81 |  $APLS | Apellis Pharmaceuticals, Inc. | $3.3M | 0.1% | NEW | 63.9 |
| 82 |  $OM | Outset Medical, Inc. | $3.2M | 0.1% | +0% | 17.6 |
| 83 |  $EDSA | Edesa Biotech, Inc. | $2.9M | 0.1% | NEW | — |
| 84 |  $ADPT | Adaptive Biotechnologies Corp | $2.1M | 0.0% | NEW | 35.2 |
| 85 |  $AVTX | Avalo Therapeutics, Inc. | $2.1M | 0.0% | +0% | 4.6 |
| 86 |  $CNTB | Connect Biopharma Holdings Ltd | $2.1M | 0.0% | +0% | — |
| 87 |  $CORT | CORCEPT THERAPEUTICS INC | $2.0M | 0.0% | NEW | 55.4 |
| 88 |  $MDLN | Medline Inc. | $1.2M | 0.0% | +0% | — |
| 89 |  $PTN | PALATIN TECHNOLOGIES INC | $1.1M | 0.0% | -12% | — |
| 90 |  $CPIX | CUMBERLAND PHARMACEUTICALS INC | $640,179 | 0.0% | -42% | 34.6 |
| 91 | $RVMD | Revolution Medicines, Inc. | $447,500 | 0.0% | +0% | — |
| 92 |  $XGN | EXAGEN INC. | $344,679 | 0.0% | NEW | 25.2 |
| 93 |  $ENSC | Ensysce Biosciences, Inc. | $46,670 | 0.0% | +0% | — |
| 94 | $SRZN | Surrozen, Inc./DE | $2,667 | 0.0% | +0% | — |
New Positions (18)
$MRNAPUT Moderna, Inc.$50.8M$IONS IONIS PHARMACEUTICALS INC$37.8M$DAWN Day One Biopharmaceuticals, Inc.$37.6M$DMRA Damora Therapeutics, Inc.$31.7M$DBVT DBV Technologies S.A.$20.1M$STRO SUTRO BIOPHARMA, INC.$17.8M$EVMN Evommune, Inc.$10.3M$PHAT Phathom Pharmaceuticals, Inc.$10.3M$NMRA Neumora Therapeutics, Inc.$10.0M$TWST Twist Bioscience Corp$7.1M$AGMB Agomab Therapeutics NV$6.3M$EOLS Evolus, Inc.$5.3M$OCULCALL OCULAR THERAPEUTIX, INC$4.2M$APLS Apellis Pharmaceuticals, Inc.$3.3M$EDSA Edesa Biotech, Inc.$2.9MExited Positions (42)
$EXK ENDEAVOUR SILVER CORP
$ACLX Arcellx, Inc.
$BSX BOSTON SCIENTIFIC CORP
$FOLD AMICUS THERAPEUTICS, INC.
$DHR DANAHER CORP /DE/
$IRON Disc Medicine, Inc.
$PEN Penumbra Inc
$CAI Caris Life Sciences, Inc.
$RAPT RAPT Therapeutics, Inc.
$PVLA PALVELLA THERAPEUTICS, INC.
$KOD Kodiak Sciences Inc.
$BIIB BIOGEN INC.Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for PERCEPTIVE ADVISORS LLC including:
Track PERCEPTIVE ADVISORS LLC's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for PERCEPTIVE ADVISORS LLC and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: PERCEPTIVE ADVISORS LLC
13F Pro is an AI hedge fund tracker and stock research platform. For PERCEPTIVE ADVISORS LLC (SEC CIK: 1224962), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in PERCEPTIVE ADVISORS LLC's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.